Preoperative Radiotherapy in Patients With Primary Retroperitoneal Sarcoma: EORTC-62092 Trial (STRASS) Versus Off-trial (STREXIT) Results

• Published in: Annals of surgery Vol. 278; no. 1; p. 127
• Main Authors: Callegaro, Dario, Raut, Chandrajit P, Ajayi, Taiwo, Strauss, Dirk, Bonvalot, Sylvie, Ng, Deanna, Stoeckle, Eberhard, Fairweather, Mark, Rutkowski, Piotr, van Houdt, Winan J, Gelderblom, Hans, Sangalli, Claudia, Hayes, Andrew, Honoré, Charles, Gladdy, Rebecca A, Fau, Magali, Haas, Rick, Tzanis, Dimitri, Miah, Aisha B, Chung, Peter, Baldini, Elizabeth H, Marreaud, Sandrine, Litiere, Saskia, Swallow, Carol J, Gronchi, Alessandro
• Format: Journal Article
• Language: English
• Published: United States 01.07.2023
• ISSN: 1528-1140
• DOI: 10.1097/SLA.0000000000005492

The aim of the present study was to compare the effect of radiotherapy (RT) on abdominal recurrence-free survival (ARFS) in patients with primary retroperitoneal sarcoma treated in the EORTC-STBSG-62092 (STRASS) phase 3 randomized controlled trial (STRASS cohort) and off-trial (STREXIT cohort) and to pool STRASS and STREXIT data to test the hypothesis that RT improves ARFS in patients with liposarcoma. The STRASS trial did not show any difference in ARFS between patients treated with preoperative radiotherapy+surgery (RT+S) versus surgery alone (S). All consecutive adult patients not enrolled in STRASS and underwent curative-intent surgery for a primary retroperitoneal sarcoma with or without preoperative RT between 2012 and 2017 (STRASS recruiting period) among ten STRASS-recruiting centres formed the STREXIT cohort. The effect of RT in STREXIT was explored with a propensity score (PS)-matching analysis. Primary endpoint was ARFS defined as macroscopically incomplete resection or abdominal recurrence or death of any cause, whichever occurred first. STRASS included 266 patients, STREXIT included 831 patients (727 after excluding patients who received preoperative chemotherapy, 202 after 1:1 PS-matching). The effect of RT on ARFS in STRASS and 1:1 PS-matched STREXIT cohorts, overall and in patients with liposarcoma, was similar. In the pooled cohort analysis, RT administration was associated with better ARFS in patients with liposarcoma [N=321, hazard ratio (HR), 0.61; 95% confidence interval (CI), 0.42-0.89]. In particular, patients with well-differentiated liposarcoma and G1-2 dedifferentiated liposarcoma (G1-2 DDLPS, n=266) treated with RT+S had better ARFS (HR, 0.63; 95% CI, 0.40-0.97) while patients with G3 DDLPS and leiomyosarcoma had not. At the current follow-up, there was no association between RT and overall survival or distant metastases-free survival. In this study, preoperative RT was associated with better ARFS in patients with primary well-differentiated liposarcoma and G1-2 DDLPS.